Alan Lau

10.1k citations

64 papers · 7.7k · 3 hit papers · h-index 32

Impact in

Oncology top 0.2%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Cancer Research top 1%
- Cancer Genomics and Diagnostics

Papers in

Molecular Biology 41
- DNA Repair Mechanisms 36
- Cancer therapeutics and mechanisms 10
- CRISPR and Genetic Engineering 6
Oncology 40
- PARP inhibition in cancer therapy 30
- Cancer-related Molecular Pathways 6

Co-authors: Mark J. O’Connor (28 shared papers)Timothy A. Yap (2 shared papers)Johann S. de Bono (1 shared paper)David S. Boss (1 shared paper)Alan Ashworth (1 shared paper)Helen Swaisland (1 shared paper)James Carmichael (2 shared papers)Stan B. Kaye (1 shared paper)
Journals: Cancer Research (13 papers)Molecular Cancer Therapeutics (9 papers)Journal of Medicinal Chemistry (4 papers)Clinical Cancer Research (4 papers)British Journal of Cancer (4 papers)
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Alan Lau

62 papers receiving 7.6k citations

Alan Lau's Hit Papers

align trajectories log scale

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers 2009 · 2.9k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 New England Journal of Medicine
2008 Journal of Medicinal Chemistry
2008 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Alan Lau

Since Specialization

Citations

This map shows the geographic impact of Alan Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Lau more than expected).

Fields of papers citing papers by Alan Lau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Lau. The network helps show where Alan Lau may publish in the future.

Co-authors

The 25 scholars most cited alongside Alan Lau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan Lau Line = papers co-authored together Alan Lau links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 64 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers New England Journal of Medicine ·Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono Hit paper breakdown →	2009	2851
2	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proceedings of the National Academy of Sciences ·Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O.H. Nygren, Serge A.L. Zander, Patrick W.B. Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau, Robert Boulter, Aaron Cranston, Mark J. O’Connor, Niall M.B. Martin, Piet Borst, Jos Jonkers Hit paper breakdown →	2008	790
3	4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1 Journal of Medicinal Chemistry ·Keith Menear, Claire Adcock, Robert Boulter, Xiaoling Cockcroft, Louise Copsey, Aaron Cranston, Krystyna J. Dillon, Jan Drzewiecki, Sheila Garman, Sylvie Gomez, Hashim Javaid, Frank Kerrigan, Charlotte Knights, Alan Lau, Vincent M. Loh, Ian T.W. Matthews, Stephen Moore, Mark J. O’Connor, Graeme C.M. Smith, Niall M.B. Martin Hit paper breakdown →	2008	501
4	Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors Cancer Discovery ·Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly, James H. Doroshow, Aaron Cranston, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Shridar Ganesan, Piet Borst, Jos Jonkers, Sven Rottenberg	2012	398
5	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin Clinical Cancer Research ·Bastiaan Evers, Rinske Drost, Eva Schut, Michiel de Bruin, Eline van der Burg, Patrick W.B. Derksen, Henne Holstege, Xiaoling Liu, Ellen van Drunen, H. Berna Beverloo, Graeme C.M. Smith, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Jos Jonkers	2008	273
6	Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent Journal of Medicinal Chemistry ·Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire, Paul Turner, Sylvie M. Guichard, James Yates, Alan Lau, Kevin Blades, Dan Heathcote, Rajesh Odedra, Gary Wilkinson, Zena Wilson, Christine Wood, Philip J. Jewsbury	2018	239
7	The overexpression of specialized DNA polymerases in cancer DNA repair ·Mark R. Albertella, Alan Lau, Mark J. O’Connor	2005	220
8	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells Blood ·Marwan Kwok, Nicholas Davies, Angelo Agathanggelou, Edward Smith, Ceri Oldreive, Eva Petermann, Grant S. Stewart, Jeff Brown, Alan Lau, Guy Pratt, Helen Parry, A. Malcolm R. Taylor, Paul Moss, Peter Hillmen, Tatjana Stanković	2015	218
9	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancerin vivo Oncotarget ·Frank P. Vendetti, Alan Lau, Sandra Schamus, Thomas P. Conrads, Mark J. O’Connor, Christopher J. Bakkenist	2015	199
10	ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation Clinical Cancer Research ·Laura Biddlestone-Thorpe, (unknown), Elizabeth Rosenberg, Jason M. Beckta, Nicholas C.K. Valerie, Mary Tokarz, Bret R. Adams, Alison F. Wagner, Ashraf Khalil, Donna Gilfor, Sarah E. Golding, Sumitra Deb, David G. Temesi, Alan Lau, Mark J. O’Connor, Kevin S. Choe, Luis F. Parada, Sang Kyun Lim, Nitai D. Mukhopadhyay, Kristoffer Valerie	2013	162
11	Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment Cell Cycle ·Lenka Oplustilova, Kamila Wolanin, Martin Mistrík, Gabriela Kořínková, Dana Šimková, Jan Bouchal, René Lenobel, Jiřina Bártková, Alan Lau, Mark J. O’Connor, (unknown), Jiří Bártek	2012	132
12	Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells Oncogene ·Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya, Zena Wilson, Giuditta Illuzzi, Katarzyna Falenta, Gemma N. Jones, Neil H. James, Christophe D. Chabbert, Jonathan Stott, Emma Dean, Alan Lau, Lucy A. Young	2020	131
13	Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer Molecular Cancer Therapeutics ·Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline J. Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell, Nicola J. Curtin	2013	124
14	Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase Nature Cell Biology ·Alan Lau, Karra M. Swinbank, Parvin S. Ahmed, Debra L. Taylor, Stephen P. Jackson, Graeme C.M. Smith, Mark J. O’Connor	2005	121
15	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells Molecular Cancer Therapeutics ·Ahrum Min, Seock‐Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae‐Yong Kim, Do‐Youn Oh, Jeff Brown, Alan Lau, Mark J. O’Connor, Yung‐Jue Bang	2017	110
16	Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival Journal of Medicinal Chemistry ·Jason G. Kettle, Husam Alwan, Michał Biśta, J. Breed, Nichola L. Davies, Kay Eckersley, Shaun Fillery, Kevin M. Foote, Louise Goodwin, David R. Jones, Helena Käck, Alan Lau, J. Willem M. Nissink, Jon Read, James S. Scott, Ben Taylor, Graeme E. Walker, Lisa Wissler, Marta Wylot	2016	103
17	Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin Cancer Research ·Trevor Hay, James R. Matthews, Lucie Pietzka, Alan Lau, Aaron Cranston, Anders O.H. Nygren, Anthony Douglas-Jones, Graeme C.M. Smith, Niall M.B. Martin, Mark J. O’Connor, Alan R. Clarke	2009	97
18	The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression Molecular Cancer Therapeutics ·Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang‐Boon Koh, Chiara Fornari, James Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards, Duncan I. Jodrell	2018	82
19	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study Clinical Cancer Research ·Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay, Anthony El-Khouiery, Jean‐Charles Soria, Juanita Lopez, Aliénor Berges, S. Y. Amy Cheung, Itziar Irurzun‐Arana, Andrew Goldwin, Brunella Felicetti, Gemma N. Jones, Alan Lau, Paul Frewer, Andrew J. Pierce, Glen Clack, Christine Stephens, Simon A. Smith, Emma Dean, Simon J. Hollingsworth	2021	78
20	Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway The Lancet ·Marwan Kwok, Nicholas Davies, Angelo Agathanggelou, Edward Smith, Eva Petermann, Eliot Yates, Jeffrey S. Brown, Alan Lau, Tatjana Stanković	2015	70

About Alan Lau

Alan Lau is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Genetics and Genetics, having authored 64 papers that have together received 7.7k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (36 papers), PARP inhibition in cancer therapy (30 papers), Cancer therapeutics and mechanisms (10 papers), Cancer-related Molecular Pathways (6 papers), CRISPR and Genetic Engineering (6 papers), BRCA gene mutations in cancer (5 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). The work is most often cited by research in Oncology (4.9k citations), Cancer Research (976 citations), Molecular Biology (4.7k citations), Reproductive Medicine (454 citations) and Genetics (1.1k citations). Alan Lau has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Mark J. O’Connor, Timothy A. Yap, Johann S. de Bono, David S. Boss, Alan Ashworth, Helen Swaisland, James Carmichael, Stan B. Kaye, Andrew Tutt and Peijun Wu. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, Clinical Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Alan Lau

Impact in

Papers in i

In The Last Decade

Alan Lau

Alan Lau's Hit Papers

Peers

Countries citing papers authored by Alan Lau

Fields of papers citing papers by Alan Lau

All Works

About Alan Lau

Explore authors with similar magnitude of impact

Papers in